Amol Akhade, Consultant Medical Oncologist atSuyog Cancer Clinics, shared a post on X:
“Everolimus vs Alpelisib vs Capivasertib.
Even though PFS HR are similar for all 3 drugs, only capivasertib has phase III data in patients with cdk4- 6 exposure.
Toxicity profile for capivasertib is better as compared to alpelisib, especially for rash and hyperglycaemia.”
Source: Amol Akhade/X
